Takeda Pharmaceutical Co Ltd
TAK17.890USD
+0.095+0.53%
終値 02/06, 16:00（ET）15分遅れの株価
56.52B時価総額
77.89直近12ヶ月PER
詳細情報 Takeda Pharmaceutical Co Ltd 企業名
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltdの企業情報
企業コードTAK
会社名Takeda Pharmaceutical Co Ltd
上場日Jun 21, 2085
最高経営責任者「CEO」Weber (Christophe)
従業員数47455
証券種類Depository Receipt
決算期末Jun 21
本社所在地4F
都市CHUO-KU
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国Japan
郵便番号103-8668
電話番号81332782111
ウェブサイトhttps://www.takeda.com/
企業コードTAK
上場日Jun 21, 2085
最高経営責任者「CEO」Weber (Christophe)
Takeda Pharmaceutical Co Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Gastrointestinal diseases
353.49B
31.77%
Plasma derivatives
256.53B
23.05%
Rare diseases
184.12B
16.55%
Oncology
149.03B
13.39%
Neuroscience
97.55B
8.77%
他の
72.06B
6.48%
地域別USD
会社名
収益
比率
United States
545.17B
48.99%
Europe And Canada (Country)
272.90B
24.52%
Japan
111.06B
9.98%
Latin America
60.92B
5.47%
China (Country)
49.45B
4.44%
他の
73.28B
6.59%
事業別
地域別
事業別USD
会社名
収益
比率
Gastrointestinal diseases
353.49B
31.77%
Plasma derivatives
256.53B
23.05%
Rare diseases
184.12B
16.55%
Oncology
149.03B
13.39%
Neuroscience
97.55B
8.77%
他の
72.06B
6.48%
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
他の
99.00%
株主統計
株主統計
比率
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
他の
99.00%
種類
株主統計
比率
Investment Advisor
1.82%
Hedge Fund
0.32%
Investment Advisor/Hedge Fund
0.32%
Research Firm
0.21%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
他の
97.29%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
616
84.00M
2.66%
-4.46M
2025Q3
606
78.67M
2.49%
-1.76M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Capital Research Global Investors
13.40M
0.42%
+108.56K
+0.82%
Sep 30, 2025
Parametric Portfolio Associates LLC
6.05M
0.19%
+74.59K
+1.25%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.17M
0.13%
+85.28K
+2.09%
Sep 30, 2025
UBS Financial Services, Inc.
5.86M
0.19%
+1.88M
+47.19%
Sep 30, 2025
Brandes Investment Partners, L.P.
3.93M
0.12%
+219.53K
+5.91%
Sep 30, 2025
Renaissance Technologies LLC
3.86M
0.12%
+565.40K
+17.14%
Sep 30, 2025
Goldman Sachs Asset Management, L.P.
3.33M
0.11%
+481.85K
+16.91%
Sep 30, 2025
Aperio Group, LLC
3.31M
0.1%
+100.83K
+3.15%
Sep 30, 2025
TD Securities, Inc.
3.00M
0.1%
+3.00M
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
2.83M
0.09%
+1.61M
+132.12%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
VanEck Pharmaceutical ETF
5.05%
SGI Enhanced Global Income ETF
0.76%
Adasina Social Justice All Cap Global ETF
0.49%
First Trust Value Line Dividend Index Fund
0.38%
ActivePassive International Equity ETF
0.3%
Avantis Responsible International Equity ETF
0.09%
Avantis International Equity ETF
0.05%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
詳細を見る
VanEck Pharmaceutical ETF
比率5.05%
SGI Enhanced Global Income ETF
比率0.76%
Adasina Social Justice All Cap Global ETF
比率0.49%
First Trust Value Line Dividend Index Fund
比率0.38%
ActivePassive International Equity ETF
比率0.3%
Avantis Responsible International Equity ETF
比率0.09%
Avantis International Equity ETF
比率0.05%
Roundhill GLP-1 & Weight Loss ETF
比率0%
DFA Dimensional International Core Equity 2 ETF
比率0%
Invesco Zacks Multi-Asset Income ETF
比率0%
配当金
過去5年間の配当金総支払額は
1.44T
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Sep 08, 2025
TAK.NB Final Cash Dividend of gross USD 0.322144 paid on Dec 11, 2025 going ex on Sep 30, 2025
Sep 30, 2025
Dec 11, 2025
Sep 30, 2025
Mar 04, 2025
TAK.NB Approximate interim Cash Dividend of gross USD 0.33901 paid on Jul 07, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Jul 07, 2025
Mar 31, 2025
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
